Refractor

Main information

  • Trade name:
  • Refractor, ophthalmic
  • Class:
  • Class IIa
  • Medicine domain:
  • Humans
  • Medicine type:
  • Medical device

Documents

Localization

  • Available in:
  • Refractor, ophthalmic
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 221467
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

221467

Carl Zeiss Pty Ltd - Refractor, ophthalmic

ARTG entry for

Medical Device Included Class IIa

Sponsor

Carl Zeiss Pty Ltd

Postal Address

PO Box 501,NORTH RYDE BC, NSW, 1670

Australia

ARTG Start Date

19/03/2014

Product category

Medical Device Class IIa

Status

Active

Approval area

Medical Devices

Conditions

- The inclusion of the kind of device in the ARTG is subject to compliance with all conditions placed or imposed on the ARTG entry. Refer Part 4-5,

Division 2 (Conditions) of the Therapeutic Goods Act 1989 and Part 5, Division 5.2 (Conditions) of the Therapeutic Goods (Medical Devices) Regulations

2002 for relevant information.

- Breaching conditions of the inclusion related to the device of the kind may lead to suspension or cancellation of the ARTG entry; may be a criminal

offence; and civil penalties may apply.

Manufacturers

Name

Address

Carl Zeiss Vision GmbH

Turnstrasse 27

Aalen, , D-73430

Germany

Products

1. Refractor, ophthalmic

Product Type

Single Device Product

Effective date

19/03/2014

GMDN

35299 Refractor, ophthalmic

Intended purpose

This device is a diagnostic instrument for measuring and analyzing imaging errors and corneal surfaces.

Specific Conditions

No Specific Conditions included on Record

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 10.11.2017 at 12:58:13 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

13-9-2018

FDA approves new kind of treatment for hairy cell leukemia

FDA approves new kind of treatment for hairy cell leukemia

FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia

FDA - U.S. Food and Drug Administration

8-8-2018

FDA approves treatment for two rare types of non-Hodgkin lymphoma

FDA approves treatment for two rare types of non-Hodgkin lymphoma

FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy

FDA - U.S. Food and Drug Administration

20-7-2018

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

FDA approves new drug for the treatment of adults with acute myeloid leukemia who have a specific genetic mutation and a companion diagnostic to detect specific mutations in the IDH1 gene in patients with AML

FDA - U.S. Food and Drug Administration

There are no news related to this product.